Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP)
Showing 1 - 25 of 1,891
Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)
Not yet recruiting
- Ovarian Cancer Recurrent
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jan 5, 2023
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or
Completed
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Avelumab Phase 1b
- +3 more
-
Fayetteville, Arkansas
- +57 more
Jan 18, 2023
Breast Tumors, Triple-Negative, Breast Tumor Malignant Female, Radiotherapy Side Effect Trial in Paris (Olaparib, Radiation
Active, not recruiting
- Breast Neoplasms, Triple-Negative
- +2 more
- Olaparib
- Radiation therapy
-
Paris, FranceInstitut Curie
Oct 23, 2020
Ovarian Cancer Trial in Worldwide (Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by
Completed
- Ovarian Cancer
- Chemotherapy + avelumab followed by avelumab + talazoparib
- +2 more
-
Phoenix, Arizona
- +71 more
Jul 21, 2022
HRD and Resistance to PAPPi in EOC Patients
Recruiting
- Epithelial Ovarian Cancer
- +6 more
- Testing of homologous recombination deficiency
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Prostate Cancer Trial in Philadelphia ([18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1)
Active, not recruiting
- Prostate Cancer
- [18F]FluorThanatrace
- Poly(ADP Ribose) Polymerase 1
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
May 12, 2022
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
Homologous Recombination Deficiency in Chinese Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- +2 more
- PARP inhibitor
-
Nanjing, Jiangsu, ChinaXiaoxiang Chen, MD,PhD
Sep 4, 2021
Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle
Recruiting
- Sarcoma,Soft Tissue
- +2 more
- Fluzoparib
- Radioactive particle implantation
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 30, 2023
NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- Parimparib
- +2 more
-
Wuxi, Jiangsu, ChinaAffiliated Hospital of Jiangnan University
Jan 30, 2023
Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +4 more
-
Phoenix, Arizona
- +14 more
Sep 1, 2022
Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)
Recruiting
- Recurrent Glioma
- +4 more
-
Hong Kong, Hong KongDepartment of Clinical Oncology
Aug 19, 2021
Tumors, Breast Tumors Trial in Japan (talazoparib)
Active, not recruiting
- Neoplasms
- Breast Neoplasms
-
Nagoya, Aichi, Japan
- +7 more
Dec 20, 2021
Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)
Active, not recruiting
- Acute Myeloid Leukemia
-
Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022
Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination
Recruiting
- Advanced Solid Tumors
- KSQ-4279
- KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
-
Boston, Massachusetts
- +4 more
Apr 5, 2022
Ovarian Tumors Trial in United States (Niraparib, Bevacizumab)
Active, not recruiting
- Ovarian Neoplasms
- Niraparib
- Bevacizumab
-
Mobile, Alabama
- +27 more
Nov 23, 2022
Urothelial Cancer Trial in Spain (Niraparib plus Cabozantinib)
Recruiting
- Urothelial Cancer
- Niraparib plus Cabozantinib
-
Barcelona, Cataluña, Spain
- +10 more
Feb 8, 2022
Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)
Recruiting
- Breast Cancer
- Talazoparib
- Sacituzumab Govitecan
-
Boston, Massachusetts
- +1 more
Jan 6, 2023
Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Tumor Trial in New Brunswick
Active, not recruiting
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- +2 more
- Cyclophosphamide
- +4 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 28, 2023
Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)
Completed
- Metastatic Cancer
- Unspecified Adult Solid Tumor
- PARP inhibitor BMN-673
- +4 more
-
Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
Sep 22, 2022
Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)
Active, not recruiting
- Metastatic Breast Cancer
- PARP inhibitor 2X-121
-
Herlev, Denmark
- +1 more
Feb 1, 2023